Safety and efficacy of radioembolization in elderly (≥ 70 years) and younger patients with unresectable liver-dominant colorectal cancer

Andrew S. Kennedy, David S. Ball, Steven J. Cohen, Michael Cohn, Douglas Coldwell, Alain Drooz, Eduardo Ehrenwald, Samir Kanani, Steven C. Rose, Charles W. Nutting, Fred M. Moeslein, Michael A. Savin, Sabine Schirm, Samuel G. Putnam, Navesh K. Sharma, Eric A. Wang

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Background The effects of advancing age on clinical outcomes after radioembolization (RE) in patients with unresectable liver-dominant metastatic colorectal cancer (mCRC) are largely unknown. Patients and Methods This study was a retrospective analysis of 160 elderly (≥ 70 years) and 446 younger (< 70 years) consecutive patients from 11 US centers who received RE using ytrrium-90 (90Y) resin microspheres (90Y radioembolization [90Y-RE]) between July 2002 and December 2011. A further analysis was conducted in 98 very elderly patients (≥ 75 years). Statistical analyses of safety, tolerability, and overall survival were conducted. Results Mean ages (± standard deviation) in the younger (< 70 years), elderly (≥ 70 years), and very elderly (≥ 75 years) cohorts were 55.9 ± 9.4 years, 77.2 ± 4.8 years, and 80.2 ± 3.8 years, respectively. Overall survival was similar between elderly and younger patients: 9.3 months (95% confidence interval [CI], 8.0-12.1) and 9.7 months (95% CI, 9.0-11.4) (P =.335). There were no differences between cohorts for any grade adverse events (P =.433) or grade 3+ events (P =.482). Analysis of patients ≥ 75 years and < 75 years confirmed similar overall survival (median, 9.3 months vs. 9.6 months, respectively; P =.987) and grade 3+ events (P =.398) or any adverse event (P =.158) within 90 days of RE. Conclusion For patients with unresectable liver-dominant mCRC who meet eligibility criteria for RE, 90Y-RE microspheres appear to be effective and well-tolerated, regardless of age. Criteria for selecting patients for RE should not include age for exclusion from this potentially beneficial intervention.

Original languageEnglish (US)
Pages (from-to)141-151.e6
JournalClinical Colorectal Cancer
Volume15
Issue number2
DOIs
StatePublished - Jun 1 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Safety and efficacy of radioembolization in elderly (≥ 70 years) and younger patients with unresectable liver-dominant colorectal cancer'. Together they form a unique fingerprint.

Cite this